Improved Migraine Disability, Sleep Quality, and Well-Being in Individuals with Chronic Migraine Self-Administering Artisanal or Industrial Full-Spectrum Cannabidiol-Rich Oils: An Observational Cohort Study
Clinical Neuropsychopharmacology and Addiction · 2026
DOI: 10.53941/cna.2026.100002 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Clinical Neuropsychopharmacology and Addiction, 2026. Verfasst von Linério Ribeiro de Novais Júnior und 12 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Schlaf
Abstract (Originalsprache)
Background
Migraine is a highly prevalent neurological disorder. Conventional therapies may be limited by side effects and suboptimal efficacy. Cannabidiol (CBD) has emerged as a potential alternative therapy with a more favorable safety profile.
Methods
In this 12-week prospective observational cohort study, we evaluated the safety, feasibility, and preliminary efficacy of two full-spectrum CBD-rich oils—industrial and artisanal—for chronic migraine in 40 individuals that began self-medicating with either oil (N = 20 per group), provided through an existing initiative by an industrial company and a patient association. The oil was titrated individually to reach a target dose of 100 mg/day of CBD. Assessments were conducted using the Migraine Disability Assessment Questionnaire (MIDAS), Headache Impact Test (HIT-6), Mini Sleep Questionnaire (MSQ), and the World Health Organization Quality of Life—5-item version (WHOQOL-5).
Results
Both formulations led to improvements in migraine-related disability, headache impact, quality of life, quality of sleep, and subjective well-being. Adverse events occurred at similar rates across groups.
Conclusions
In sum, full-spectrum CBD-rich oil—both industrial and artisanal—appears effective in reducing migraine burden in individuals with chronic migraine, while maintaining an acceptable side effects profile. These findings support the need for randomized controlled trials to determine the lowest and most effective regimens, and cannabinoid compositions.
Zitieren
APA
Júnior, L. R. D. N., Silva, L. M. D., Meneguzzo, V., Ramos, S. D. S., Rosa, L. R. D., Souza, T. O. D., Simão, J. V., Silva, A. R. D., Mack, J., Kock, K. D. S., Goldim, M. P. D. S., Inserra, A., & Bitencourt, R. M. D. (2026). Improved Migraine Disability, Sleep Quality, and Well-Being in Individuals with Chronic Migraine Self-Administering Artisanal or Industrial Full-Spectrum Cannabidiol-Rich Oils: An Observational Cohort Study. Clinical Neuropsychopharmacology and Addiction. https://doi.org/10.53941/cna.2026.100002
Vancouver
Júnior LRDN, Silva LMD, Meneguzzo V, Ramos SDS, Rosa LRD, Souza TOD, et al. Improved Migraine Disability, Sleep Quality, and Well-Being in Individuals with Chronic Migraine Self-Administering Artisanal or Industrial Full-Spectrum Cannabidiol-Rich Oils: An Observational Cohort Study. Clinical Neuropsychopharmacology and Addiction. 2026. doi:10.53941/cna.2026.100002
BibTeX
@article{Jnior2026,
author = {Júnior, Linério Ribeiro de Novais and Silva, Larissa Mendes da and Meneguzzo, Vicente and Ramos, Suelen de Souza and Rosa, Lara Rodrigues da and Souza, Tiago Odilio de and Simão, João Victor and Silva, Alisson Reuel da and Mack, Josiel and Kock, Kelser de Souza and Goldim, Mariana Pereira de Souza and Inserra, Antonio and Bitencourt, Rafael Mariano de},
title = {Improved Migraine Disability, Sleep Quality, and Well-Being in Individuals with Chronic Migraine Self-Administering Artisanal or Industrial Full-Spectrum Cannabidiol-Rich Oils: An Observational Cohort Study},
journal = {Clinical Neuropsychopharmacology and Addiction},
year = {2026},
doi = {10.53941/cna.2026.100002}
}
EUVIMED